[Skip to Content]

Upstate Active Clinical Trials

Study Title:

PROMINENT Pemafibrate to Reduce cardiovascular OutcoMes by reducing triglycerides IN patiENts with diabeTes

What is the purpose of the study?

The purpose of this study is to find out if of K-877 (also called pemafibrate), the study drug, compared to placebo (a treatment which looks like the medicine but contains no active pemafibrate), lowers cardiovascular (CV) complications (also referred to as “events”), such as heart attack, stroke, and death from these conditions, in adults with type-2 diabetes mellitus (T2D) who have elevated triglycerides (TGs; one type of fat), and low high-density lipoprotein cholesterol (HDL-C; “good” cholesterol).

The study will also test whether the study drug has other possible benefits in patients with diabetes, and will test the safety of the study drug. To answer these questions, it is important for patients to be in the study until the end even if they stop taking the study drug earlier.

Upstate Institutional Review Board (IRB) Number:

1023277

Study/Protocol ID:

K-877-302

Study Phase:

Phase III

Patient Age Group:

Adults

Principal Investigator:

Ruth S Weinstock, MD, PhD

Who can I contact for more information?

Name: Suzan M Bzdick, RN
Phone: 315-464-9006
Email: bzdicks@upstate.edu

Return to Previous Page || Search Again

Top